{"DataElement":{"publicId":"2540945","version":"1","preferredName":"AIDS Malignancy Consortium Patient Inclusion Clinical Trial Eligibility Criteria 047 Type","preferredDefinition":"the type of element of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial of a person who receives medical attention, care, or treatment in a clinical trials cooperative group supported by NCI.","longName":"AMC_PT_I_CTEC_047_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2518231","version":"1","preferredName":"AIDS Malignancy Consortium Patient Inclusion Clinical Trial Eligibility Criteria","preferredDefinition":"information relating to the elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial of a person who receives medical attention, care, or treatment in a clinical trials cooperative group supported by NCI.","longName":"AMC_PT_INCL_CTEC","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2518228","version":"1","preferredName":"AIDS Malignancy Consortium Patient","preferredDefinition":"Established in 1995 to carry out Phase I and II studies of innovative therapies for AIDS malignancies.:A person who requires medical care.","longName":"C19707:C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AIDS Malignancy Consortium","conceptCode":"C19707","definition":"Established in 1995 to carry out Phase I and II studies of innovative therapies for AIDS malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1CC96D39-08C6-6793-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2518229","version":"1","preferredName":"Inclusion Clinical Trial Eligibility Criteria","preferredDefinition":"The addition of somebody or something to, or the presence of somebody or something in, a group or mixture, particularly, a passive, usually temporary, product of cell activity within the cytoplasm or nucleus.:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C25532:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inclusion Criteria","conceptCode":"C25532","definition":"Medical and/or social characteristics which are necessary for a subject to be allowed to participate in a clinical study, as outlined in the study protocol. Meeting inclusion criteria is not a sufficient condition for entry or recruitment of a subject into the study. Characteristics limiting the eligibility of a subject for the clinical study must be considered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1CC96D39-08D4-6793-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1CC977E8-B49D-6863-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2540909","version":"1","preferredName":"047 Inclusion Clinical Trial Eligibility Criteria Type","preferredDefinition":"the type of clinical trial eligibility inclusion criteria for an AIDS Malignancy Consortium 047 protocol.","longName":"047_INCL_CTEC_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"255","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Patient's age (in years)","valueDescription":"Patient's age (in years)","ValueMeaning":{"publicId":"2580740","version":"1","preferredName":"Patient's age (in years)","longName":"2580740","preferredDefinition":"Patient's age (in years)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0871-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"SHIDED","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"21E924D6-BF69-508C-E044-0003BA3F9857","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-10","modifiedBy":"ONEDATA","dateModified":"2006-11-10","deletedIndicator":"No"},{"value":"Does the subject have previously untreated, histologically or cytologically documented B-cell non-Hodgkin's lymphoma","valueDescription":"Does the subject have previously untreated, histologically or cytologically documented B-cell non-Hodgkin's lymphoma","ValueMeaning":{"publicId":"2581693","version":"1","preferredName":"Does the subject have previously untreated, histologically or cytologically documented B-cell non-Hodgkin's lymphoma","longName":"2581693","preferredDefinition":"Does the subject have previously untreated, histologically or cytologically documented B-cell non-Hodgkin's lymphoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0C2A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-10","modifiedBy":"SHIDED","dateModified":"2006-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"21E94D25-3035-50DA-E044-0003BA3F9857","beginDate":"2006-11-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-10","modifiedBy":"ONEDATA","dateModified":"2006-11-10","deletedIndicator":"No"},{"value":"Does the patient have the ability and willingness to give informed consent?","valueDescription":"Does the patient have the ability and willingness to give informed consent?","ValueMeaning":{"publicId":"2580744","version":"1","preferredName":"Does the patient have the ability and willingness to give informed consent?","longName":"2580744","preferredDefinition":"Does the patient have the ability and willingness to give informed consent?","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0875-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"SHIDED","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"21E924D6-BF91-508C-E044-0003BA3F9857","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-10","modifiedBy":"ONEDATA","dateModified":"2006-11-10","deletedIndicator":"No"},{"value":"Date informed consent obtained","valueDescription":"Date informed consent obtained","ValueMeaning":{"publicId":"2580745","version":"1","preferredName":"Date informed consent obtained","longName":"2580745","preferredDefinition":"Date informed consent obtained","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0876-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"SHIDED","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"21E924D6-BF9B-508C-E044-0003BA3F9857","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-10","modifiedBy":"ONEDATA","dateModified":"2006-11-10","deletedIndicator":"No"},{"value":"Is the disease one of the following histologies: follicular large-cell (Grade 3), DLBCL, immunoblastic, plasmablastic, or primary effusion lymphoma","valueDescription":"Is the disease one of the following histologies: follicular large-cell (Grade 3), DLBCL, immunoblastic, plasmablastic, or primary effusion lymphoma","ValueMeaning":{"publicId":"2581694","version":"1","preferredName":"Is the disease one of the following histologies: follicular large-cell (Grade 3), DLBCL, immunoblastic, plasmablastic, or primary effusion lymphoma","longName":"2581694","preferredDefinition":"Is the disease one of the following histologies: follicular large-cell (Grade 3), DLBCL, immunoblastic, plasmablastic, or primary effusion lymphoma","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0C2B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-10","modifiedBy":"SHIDED","dateModified":"2006-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"21E94D25-3047-50DA-E044-0003BA3F9857","beginDate":"2006-11-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-10","modifiedBy":"ONEDATA","dateModified":"2006-11-10","deletedIndicator":"No"},{"value":"Is the subject's lymphoma CD20-positive","valueDescription":"Is the subject's lymphoma CD20-positive","ValueMeaning":{"publicId":"2581695","version":"1","preferredName":"Is the subject's lymphoma CD20-positive","longName":"2581695","preferredDefinition":"Is the subject's lymphoma CD20-positive","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0C2C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-10","modifiedBy":"SHIDED","dateModified":"2006-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"21E94D25-3059-50DA-E044-0003BA3F9857","beginDate":"2006-11-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-10","modifiedBy":"ONEDATA","dateModified":"2006-11-10","deletedIndicator":"No"},{"value":"Does the subject have documented HIV infection (Documentation may be serologic [ELISA, western blot], culture, or quantitative PCR or bDNA assays. Prior documentation of HIV seropositivity is acceptable)","valueDescription":"Does the subject have documented HIV infection (Documentation may be serologic [ELISA, western blot], culture, or quantitative PCR or bDNA assays. Prior documentation of HIV seropositivity is acceptable)","ValueMeaning":{"publicId":"2581696","version":"1","preferredName":"Does the subject have documented HIV infection (Documentation may be serologic [ELISA, western blot], culture, or quantitative PCR or bDNA assays. Prior documentation of HIV seropositivity is acceptable)","longName":"2581696","preferredDefinition":"Does the subject have documented HIV infection (Documentation may be serologic [ELISA, western blot], culture, or quantitative PCR or bDNA assays. Prior documentation of HIV seropositivity is acceptable)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0C2D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-10","modifiedBy":"SHIDED","dateModified":"2006-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"21E94D25-306B-50DA-E044-0003BA3F9857","beginDate":"2006-11-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-10","modifiedBy":"ONEDATA","dateModified":"2006-11-10","deletedIndicator":"No"},{"value":"Does the subject have either measurable or non-measurable tumor parameter(s) Non-measurable tumor parameters are defined as not having bidimensional measurements but can be followed for response by other diagnostic tests","valueDescription":"Does the subject have either measurable or non-measurable tumor parameter(s) Non-measurable tumor parameters are defined as not having bidimensional measurements but can be followed for response by other diagnostic tests","ValueMeaning":{"publicId":"2581698","version":"1","preferredName":"Does the subject have either measurable or non-measurable tumor parameter(s) Non-measurable tumor parameters are defined as not having bidimensional measurements but can be followed for response by other diagnostic tests","longName":"2581698","preferredDefinition":"Does the subject have either measurable or non-measurable tumor parameter(s) Non-measurable tumor parameters are defined as not having bidimensional measurements but can be followed for response by other diagnostic tests","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0C2F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-10","modifiedBy":"SHIDED","dateModified":"2006-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"21E94D25-307D-50DA-E044-0003BA3F9857","beginDate":"2006-11-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-10","modifiedBy":"ONEDATA","dateModified":"2006-11-10","deletedIndicator":"No"},{"value":"Does the subject's bilirubin measure <= 2.0 mg/dL (unless elevated secondary to lymphomatous involvement of liver or biliary system, or due to other HIV medications [e.g., indinavir or atazanavir])","valueDescription":"Does the subject's bilirubin measure <= 2.0 mg/dL (unless elevated secondary to lymphomatous involvement of liver or biliary system, or due to other HIV medications [e.g., indinavir or atazanavir])","ValueMeaning":{"publicId":"2581699","version":"1","preferredName":"Does the subject's bilirubin measure <= 2.0 mg/dL (unless elevated secondary to lymphomatous involvement of liver or biliary system, or due to other HIV medications [e.g., indinavir or atazanavir])","longName":"2581699","preferredDefinition":"Does the subject's bilirubin measure <= 2.0 mg/dL (unless elevated secondary to lymphomatous involvement of liver or biliary system, or due to other HIV medications [e.g., indinavir or atazanavir])","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0C30-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-10","modifiedBy":"SHIDED","dateModified":"2006-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"21E95DA0-0FFF-508E-E044-0003BA3F9857","beginDate":"2006-11-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-10","modifiedBy":"ONEDATA","dateModified":"2006-11-10","deletedIndicator":"No"},{"value":"Does the subject's creatinine measure <= 2.0 mg/dL or is creatinine clearance >= 60 mL/min (unless secondary to renal involvement by lymphoma)","valueDescription":"Does the subject's creatinine measure <= 2.0 mg/dL or is creatinine clearance >= 60 mL/min (unless secondary to renal involvement by lymphoma)","ValueMeaning":{"publicId":"2581700","version":"1","preferredName":"Does the subject's creatinine measure <= 2.0 mg/dL or is creatinine clearance >= 60 mL/min (unless secondary to renal involvement by lymphoma)","longName":"2581700","preferredDefinition":"Does the subject's creatinine measure <= 2.0 mg/dL or is creatinine clearance >= 60 mL/min (unless secondary to renal involvement by lymphoma)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0C31-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-10","modifiedBy":"SHIDED","dateModified":"2006-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"21E95DA0-1011-508E-E044-0003BA3F9857","beginDate":"2006-11-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-10","modifiedBy":"ONEDATA","dateModified":"2006-11-10","deletedIndicator":"No"},{"value":"Do the subject's granulocytes (ANC) measure >= 1000 mm^3 and platelets >= 75,000 dL (unless these parameters are abnormal secondary to lymphomatous involvement of bone marrow, or due to HIV-related thrombocytopenia)","valueDescription":"Do the subject's granulocytes (ANC) measure >= 1000 mm^3 and platelets >= 75,000 dL (unless these parameters are abnormal secondary to lymphomatous involvement of bone marrow, or due to HIV-related thrombocytopenia)","ValueMeaning":{"publicId":"2581701","version":"1","preferredName":"Do the subject's granulocytes (ANC) measure >= 1000 mm^3 and platelets >= 75,000 dL (unless these parameters are abnormal secondary to lymphomatous involvement of bone marrow, or due to HIV-related thrombocytopenia)","longName":"2581701","preferredDefinition":"Do the subject's granulocytes (ANC) measure >= 1000 mm^3 and platelets >= 75,000 dL (unless these parameters are abnormal secondary to lymphomatous involvement of bone marrow, or due to HIV-related thrombocytopenia)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0C32-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-10","modifiedBy":"SHIDED","dateModified":"2006-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"21E95DA0-1023-508E-E044-0003BA3F9857","beginDate":"2006-11-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-10","modifiedBy":"ONEDATA","dateModified":"2006-11-10","deletedIndicator":"No"},{"value":"Is the subject's left ventricular ejection fraction (LVEF) at or above the lower institutional limits of normal, as assessed by MUGA scan or echocardiogram, obtained within the 6 weeks prior to registration","valueDescription":"Is the subject's left ventricular ejection fraction (LVEF) at or above the lower institutional limits of normal, as assessed by MUGA scan or echocardiogram, obtained within the 6 weeks prior to registration","ValueMeaning":{"publicId":"2581702","version":"1","preferredName":"Is the subject's left ventricular ejection fraction (LVEF) at or above the lower institutional limits of normal, as assessed by MUGA scan or echocardiogram, obtained within the 6 weeks prior to registration","longName":"2581702","preferredDefinition":"Is the subject's left ventricular ejection fraction (LVEF) at or above the lower institutional limits of normal, as assessed by MUGA scan or echocardiogram, obtained within the 6 weeks prior to registration","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0C33-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-10","modifiedBy":"SHIDED","dateModified":"2006-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"21E95DA0-1035-508E-E044-0003BA3F9857","beginDate":"2006-11-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-10","modifiedBy":"ONEDATA","dateModified":"2006-11-10","deletedIndicator":"No"},{"value":"If the subject is female, has she had a negative pregnancy test within 72 hours prior to study entry","valueDescription":"If the subject is female, has she had a negative pregnancy test within 72 hours prior to study entry","ValueMeaning":{"publicId":"2581703","version":"1","preferredName":"If the subject is female, has she had a negative pregnancy test within 72 hours prior to study entry","longName":"2581703","preferredDefinition":"If the subject is female, has she had a negative pregnancy test within 72 hours prior to study entry","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0C34-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-10","modifiedBy":"SHIDED","dateModified":"2006-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"21E95DA0-1047-508E-E044-0003BA3F9857","beginDate":"2006-11-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-10","modifiedBy":"ONEDATA","dateModified":"2006-11-10","deletedIndicator":"No"},{"value":"Karnofsky Performance Status (must be > 50%)","valueDescription":"Karnofsky Performance Status (must be > 50%)","ValueMeaning":{"publicId":"2581928","version":"1","preferredName":"Karnofsky Performance Status (must be > 50%)","longName":"2581928","preferredDefinition":"Karnofsky Performance Status (must be > 50%)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0D15-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-14","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-14","modifiedBy":"SHIDED","dateModified":"2006-11-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"223A2117-EFB6-3EC7-E044-0003BA3F9857","beginDate":"2006-11-14","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-14","modifiedBy":"ONEDATA","dateModified":"2006-11-14","deletedIndicator":"No"},{"value":"If the subject is female capable of childbearing, does she agree to practice adequate birth control to prevent pregnancy while receiving treatment and for six months after treatment is discontinued","valueDescription":"If the subject is female capable of childbearing, does she agree to practice adequate birth control to prevent pregnancy while receiving treatment and for six months after treatment is discontinued","ValueMeaning":{"publicId":"2581704","version":"1","preferredName":"If the subject is female capable of childbearing, does she agree to practice adequate birth control to prevent pregnancy while receiving treatment and for six months after treatment is discontinued","longName":"2581704","preferredDefinition":"If the subject is female capable of childbearing, does she agree to practice adequate birth control to prevent pregnancy while receiving treatment and for six months after treatment is discontinued","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0C35-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-10","modifiedBy":"SHIDED","dateModified":"2006-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"21E965A9-618E-504B-E044-0003BA3F9857","beginDate":"2006-11-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-10","modifiedBy":"ONEDATA","dateModified":"2006-11-10","deletedIndicator":"No"},{"value":"Is the subject receiving concurrent effective HAART (with any licensed agents, or any agent available on an expanded access program)","valueDescription":"Is the subject receiving concurrent effective HAART (with any licensed agents, or any agent available on an expanded access program)","ValueMeaning":{"publicId":"2581705","version":"1","preferredName":"Is the subject receiving concurrent effective HAART (with any licensed agents, or any agent available on an expanded access program)","longName":"2581705","preferredDefinition":"Is the subject receiving concurrent effective HAART (with any licensed agents, or any agent available on an expanded access program)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0C36-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-10","modifiedBy":"SHIDED","dateModified":"2006-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"21E965A9-61A0-504B-E044-0003BA3F9857","beginDate":"2006-11-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-10","modifiedBy":"ONEDATA","dateModified":"2006-11-10","deletedIndicator":"No"},{"value":"If the subject is a male of child fathering potential, does he agree to practice adequate birth control while receiving treatment and for six months after treatment is discontinued","valueDescription":"If the subject is a male of child fathering potential, does he agree to practice adequate birth control while receiving treatment and for six months after treatment is discontinued","ValueMeaning":{"publicId":"3006953","version":"1","preferredName":"If the subject is a male of child fathering potential, does he agree to practice adequate birth control while receiving treatment and for six months after treatment is discontinued","longName":"3006953","preferredDefinition":"If the subject is a male of child fathering potential, does he agree to practice adequate birth control while receiving treatment and for six months after treatment is discontinued","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7EDCA7F0-3766-E0D4-E040-BB89AD4357F0","latestVersionIndicator":"Yes","beginDate":"2010-02-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EDCA7F0-377F-E0D4-E040-BB89AD4357F0","beginDate":"2010-02-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-02-05","modifiedBy":"ONEDATA","dateModified":"2010-02-05","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AMC CRF:AIDS Malignancy Consortium Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"21E924D6-BF2D-508C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-10","modifiedBy":"SHIDED","dateModified":"2011-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Inclusion Criteria","type":"Preferred Question Text","description":"Inclusion Criteria","url":null,"context":"CTEP"}],"origin":"AMC CRF:AIDS Malignancy Consortium Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"21E8987D-6358-4FD8-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-10","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-11-10","modifiedBy":"CAMPBELB","dateModified":"2011-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}